Johnson & Johnson, Novo and Alphabet all invested in the clinical data platform developer’s latest round, as big data analytics moves further into healthcare.
Pharmaceutical firms Johnson & Johnson and Novo have co-led a $150m series E round for US-based clinical data platform developer Verana Health, highlighting the growing importance of data analytics in the healthcare market. GV, a subsidiary of internet and technology group Alphabet, also took part in the round, as did pharmaceutical firm Merck & Co’s…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
